Endogenous Endophthalmitis A Complication of COVID-19 Pandemic: A Case Series. (19th May 2021)

• Record Type: Journal Article
• Authors: Agarwal, Manisha; Sachdeva, Mani; Pal, Surendra; Shah, Harita; Kumar R, Madhu; Banker, Alay
• Is Part Of: Ocular immunology and inflammation. Volume 29:Number 4(2021)
• Page Start: 726
• Page End: 729
• Publication Date: 2021-05-19
• Subjects: Endogenous endophthalmitis -- COVID-19 -- immunocompromised -- corticosteroids; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2021.1945111
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose: To report six patients with endogenous endophthalmitis as a complication of COVID-19 infection. Methods: A multicentric retrospective database review of patients with a diagnosis of endogenous endophthalmitis and a history of COVID-19 infection. Results: Four of six patients were diabetics. All presented after an average duration of 40 days (Range 17–90 days) of COVID-19 infection. Two of six patients had bilateral involvement. Five of six patients had received intravenous corticosteroid for COVID-19. Two of six vitreous samples showed fungi ( Candida and Bipolaris species), two showed bacteria ( Staphylococcus species) and two samples were culture negative . Control of infection with good visual outcome in four out of eight eyes. Conclusions: COVID-19 patients with a history of hospitalization and prolonged use of systemic corticosteroids and comorbidities, for example, diabetes mellitus have a high risk of endogenous endophthalmitis. A high index of clinical suspicion with timely intervention can salvage many eyes.